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A  variety of animal  viruses acquire an envelope by a  process of budding  at  the 
surface of the infected cell. The resulting virions contain lipids which closely reflect 
those of the host plasma  membrane, whereas most cellular membrane proteins are 
effectively excluded from the viral envelope. Thus, the maturation process requires 
specific interactions among the viral proteins which are incorporated into the cellular 
plasma membrane (1-3). Reports of the packaging of cellular actin within virions of 
several groups of enveloped viruses  (4), as well as electron microscopic evidence of 
microfilaments in close association with budding virions (5), have suggested that the 
cytoskeletal network may be actively involved in the assembly and budding of these 
viruses. It seems plausible, therefore, that both the interactions among viral compo- 
nents  and  the  action  of cellular  contractile  elements  could  be  required  for  the 
maturation of enveloped viruses. 
Cytochalasin B (CB),I a metabolite of the mold Helminthosporium dematisideum, affects 
several functions of cells in culture. It has been shown to inhibit the association of 
actin  with  membrane-associated  actin-binding  protein,  thereby  preventing  actin 
polymerization (6). The drug also inhibits microfilament-dependent cellular activities 
including cell division, motility, and phagocytosis (7, 8). Other effects of CB include 
inhibition of transport of sugars and inhibition of endocytosis (9-13). 
We  have  utilized  CB  to  investigate  the  requirement  for  an  intact  cytoskeletal 
network for the maturation process of two enveloped viruses. The results described in 
this report indicate that CB treatment does not significantly impair virus assembly 
but does impair the glycosylation of viral glycoproteins. 
Materials and Methods 
Virus  and  Cells,  For  preparation  of virus  stocks,  confluent  Madin-Darby  bovine  kidney 
(MDBK) cell monolayers in  150-mm Petri dishes were infected with the A/WSN (HoN1)  strain 
of  influenza  virus  (14)  or  the  Indiana  serotype  of  vesicular  stomatitis  virus  (VSV)  at  a 
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dehydro-N-trifluoroacetylneuraminic  acid;  HA,  hemagglutinin  glycoprotein;  HAU,  hemagglutinating 
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multiplicity of-0.1 plaque-forming unit (PFU)/cell. After a 2-h adsorption at 37°C, 6 ml of 
reinforced Eagle's medium (15) containing  2% newborn calf serum (NCS)  (Biocell Laboratories, 
Los Angeles, Calif.) was added to each dish and incubation was continued at 37°C for 48 h. 
Culture fluids were harvested, clarified by centrifugation at  1,500 g for 20 min, mixed with 1/s 
vol of 5% bovine serum albumin (BSA) in Eagle's medium, and stored at -70°C. 
Plaque Assays.  Plaque assays  for influenza virus were performed on Madin-Darby canine 
kidney (MDCK) cell monolayers (16), and for VSV on BHK21-F cell monolayers (17). 
Hemagglutination Titers.  Hemagglutination titers were determined in microtiter plates using 
chicken erythrocytes, as described previously (18). 
Purification of Virus.  Culture fluids were harvested and centrifuged at 8,000 g for  15 min to 
remove cellular debris; virus was precipitated with 7% polyethylene glycol plus 2.3% NaC1 (19), 
purified by centrifugation  on a 5-40% continuous  potassium tartrate gradient (20), and dialyzed 
vs. 0.01 M sodium phosphate, pH 7.2. 
Radiolabeling of Viral Components.  MDBK cell monolayers were infected with WSN strain of 
influenza virus at a multiplicity of ~ 10 PFU/celI. After a 2-h adsorption at 37°C, the cultures 
were washed twice with warm phosphate-buffered saline (PBS)  and overlaid with serum-free 
reinforced Eagle's medium containing either [3H]leucine  (10/~Ci/ml) or [3H]glucosamine (10 
pCi/ml) plus  4C-amino acids (1.5 pCi/ml). Incubation was continued in this medium for 24 h 
at 37°C, after which the virus was harvested and purified as described above. All radioisotopes 
used in these experiments were obtained from Schwarz/Mann Div., Becton, Dickinson, & Co., 
Orangeburg, N. Y. 
Polyacrylamide Gel  Electrophoresis.  Samples  in  1%  sodium  dodecyl  sulfate  (SDS)  and  1% 
mercaptoethanol were  boiled for  1 min, after  which  glycerol  (1%) and bromophenol blue 
(0.005%) were added to each sample before layering them onto gels. 
Samples labeled with [3H]leucine were electrophoresed on 10% polyacrylamide slab gels with 
a  3.6% acrylamide stacking gel  (3-mm thickness)  for  18-20 h  at  10 mA. Unlabeled samples 
were electrophoresed on  10% polyacrylamide slab gels with a 5% acrylamide stacking gel  (1- 
mm thickness)  for  18  20 h at 5 mA. Slab gels were run in a discontinuous Tris-glycine buffer 
with 5% SDS (21). Unlabeled gels were stained with 0.2% Coomassie Brilliant Blue. 
Samples labeled with [3H]glucosamine and 14C-amino acids were electrophoresed for  18-20 
h at 5 mA on 7.5% polyacrylamide tube gels (5-mm internal diameter) with a 2.5% acrylamide 
stacking layer (22). Tube gels were run in 0.1 M sodium phosphate buffer, pH 7.2, containing 
0.1% SDS. 
Preparation of Gels for Determination of Radioactivity.  Tube gels were frozen on dry ice, sliced 
into 1-mm thick disks, and prepared for liquid scintillation counting as described previously 
(23). 
Assay ofNeuraminidase Actwity.  400/~g of purified virus were incubated with excess fetuin as 
a substrate in 0.015 M sodium phosphate, pH 5.9 containing 0.18 mM CaCl2 for 2 h, and the 
acid butanol-soluble  reaction product examined spectrophotometrically at 549 nm, as described 
by Warren (24). Activity is expressed as neuraminidase  units, calculated according to a formula 
described previously (25). 
Electron Microscopy.  Virus-infected ceils were fixed in 1% glutaraldehyde in PBS, postfixed 
in osmium tetroxide, dehydrated in ethanol, and embedded in an epoxy resin mixture. Thin 
sections were stained with uranyl acetate and lead citrate and examined with a  Philips 301 
electron microscope (Philips Electronic Instruments, Inc., Mahwah, N. J.)  (26). 
Results 
Effects of Cytochalasin  B on Virus Release.  Confluent monolayers of MDBK cells were 
infected  with  influenza virus  under  single cycle  conditions and  incubated in  the 
presence or absence of varying concentrations of CB  (Sigma Chemical Co. St. Louis, 
Mo.). In all cases in which CB was added to the maintenance medium, it was present 
during the entire incubation period. Because CB was dissolved in a final concentration 
of 0.5% dimethyl sulfoxide (DMSO), the same concentration of DMSO was added to 
control cultures. After a  12-  to 24-h incubation, hemagglutination (HA)  titers were JOHANNA A.  GRIFFIN AND  RICHARD W.  COMPANS 
TABLE  I 
Effect of Cytochalasin B on Yield of Influenza Virus 
Treatment 
CB  N'ase 
Virus yield  Percentage of 
control 
gg/ml  U/ml  HA U/ml  % 
0  0  1,024  100 
10  0  256  25 
25  0  128  12.5 
50  0  16  1.6 
0  5  1,024  100 
50  5  512  50 
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WSN strain of influenza virus grown in MDBK cells (multiplicity of infection 
[m.o.i.] =  20 PFU/celI) in the presence of varying concentrations of CB with 
or without  1I. cholera N'ase. HAU, hemagglutinating units; N'ase, neuramini- 
dase. 
determined  on medium  from each culture.  The results,  shown  in Table  I, revealed 
that HA titers were reduced in proportion to CB concentration. At a concentration of 
50 gg/ml,  >98%  reduction  was  observed  in  titers  of influenza  virus  grown  in  the 
presence  of CB  as  compared  to controls.  These  data  indicate  that  the  drug  has  a 
dramatic effect on some aspect of influenza virus production. The results of infectivity 
titrations  show that  the reduction  in HA titers  is  paralleled  by a  drop  in infectious 
virus production  (see below). 
Electron  Microscopy of CB-Treated Cultures.  To further characterize the effects of CB 
on influenza  virus  infected  cells,  we examined  drug-treated  and  untreated  cells  by 
phase  contrast  and  by  thin-section  electron  microscopy.  Examination  by  phase 
contrast showed that  30 min after CB treatment,  cells were morphologically distinct 
from untreated  cells  in  that  they were  rounded  and  less well  spread  on  the  plastic 
surface. Electron micrographs showed fewer microvilli on surfaces of CB-treated cells 
and disappearance of the dense mesh of cytoskeletal elements along the plastic-bound 
surfaces of these cells. 
The pattern  of virus maturation  and release at  plasma membranes of control and 
drug-treated  cells was also  markedly  different.  In control  cultures,  individual  virus 
particles  were  observed  on  cell  surfaces  or in  the  process  of budding  (Fig.  1 A).  In 
contrast, cells from CB-treated cultures showed large clusters of virus adhering to their 
surfaces  (Fig.  1 B).  These  results  indicated  that  the  CB-induced  reduction  in  virus 
titers was not entirely a result of the failure of particles to be produced by CB-treated 
cells, but rather, a result of the failure of many particles to be released into the culture 
medium. 
Effects of Neuraminidase on  Virus Release.  The large aggregates of virus particles on 
surfaces of CB-treated  cells were strikingly similar  to those observed  previously (27) 
with  ts  mutants  of influenza  virus defective  in neuraminidase  activity,  and  to virus 
aggregates observed upon treatment of influenza virus-infected cells with 2-deoxy-2,3- 
dehydro-N-trifluoroacetylneuraminic acid (FANA), a synthetic neuraminidase inhib- 
itor (28). These results had suggested that an active viral neuraminidase was probably 
required  to cleave neuraminic  acid  (the  HA receptor)  from viral  and  cell  surfaces, 
and  that  a  defect  in  the  enzyme resulted  in  aggregation of the  virus by binding of 
hemagglutinin to neuraminic acid residues  (27, 28). Addition of purified  Vibrio cholera 382  MATURATION  OF  ENVELOPED  VIRUSES 
FIG.  I.  Electron micrographs of MDBK cells  12-h postinfection with influenza A/WSN.  (m.o.i. 
=  20 PFU/celI). (A) Cells incubated in the absence of CB showing individual particles budding or 
adhering to the cell surface. (B) Cells  incubated in the presence of 50/tg/rnl of CB showing large 
aggregates of extracellular virus particles. The drug was present in culture medium for the entire 
incubation period. Magnification: A,  ×  25,000;  B,  ×  25,000. 
neuraminidase  to  cultures  infected  with  the  ts  mutants  resulted  in  dispersal  of the 
aggregates with a  concurrent  enhancement  in virus titers. 
If virus produced  in the presence of CB were  lacking neuraminidase  activity, then 
the  addition  of  purified  bacterial  neuraminidase  to  CB-treated  cultures  should JOHANNA  A.  GRIFFIN  AND  RICHARD  W.  COMPANS 
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Fic.  2.  Infectivity  titers  of supernatant  medium  from  cultures  of MDBK  cells  infected  24  h 
previously with 2 PFU/cell of VSV or influenza A/WSN. CB (50 #g/ml) was present in each drug- 
treated  culture  for  the  entire  incubation  period.  Some  influenza  virus-infected  cultures  were 
additionally treated with 5 U/ml of V. cholera neuraminidase. VSV was assayed in BHK21-F cells; 
influenza virus was assayed in MDCK cells. 
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enhance particle release. Influenza virus-infected cultures containing 0  or 50/xg/ml 
CB were therefore treated with 5 U/ml of purified  V. cholera neuraminidase  (Calbi- 
ochem-Behring Corp., American Hoechst Corp., San Diego, Calif.). As a result of this 
treatment, titers of CB-grown virus rose to within 2-fold of those of untreated controls. 
Control virus titers were unaltered by neuraminidase treatment  (Table I, lines 5 and 
6).  The  recovery  of high  levels  of virus  from  CB-treated  cells  in  the  presence  of 
neuraminidase indicates that the disruption of the cytoskeletal network per se did not 
significantly alter the maturation of these viruses, but that CB treatment resulted in 
a defect in viral neuraminidase activity. 
Infectivity of Virions Produced in the Presence of CB.  To further characterize the virus 
particles produced in the presence of CB, we assayed the infectivity of virions produced 
under these conditions. MDBK cells were infected with 20 PFU/cell of influenza virus 
or  VSV  in  the  presence of 0  or  50  p,g/ml  CB  and  the  infective virus  yields were 
determined  by  plaque  assay.  As  shown  in  Fig.  2,  the  titer  of VSV  grown  in  the 
presence of CB was 84.5% of the nontreated control. Influenza virus yields from CB- 
treated cells were <5% of control virus.  However, when CB-treated influenza virus- 
infected cells were treated with 5 U/ml of exogenous neuraminidase, there was a  20- 
fold increase in infectious virus and the resulting titers were >50% of control values. 
These results indicate that CB-treated cells produce high yields of infectious influenza 
virus particles, if neuraminidase is added to overcome the block in virus release. 
Assay of Neuraminidase Activity.  We determined the neuraminidase activity (Mate- 
rials  and  Methods)  of purified  influenza  virus  grown  in  the  presence  and  in  the 
absence  of CB.  Table  II  shows  that  CB  treatment  of cells  resulted  in  a  10-fold 
reduction in specific activity of neuraminidase of purified virions obtained from these 
cells.  Because exogenous neuraminidase was added to all cultures to enhance virion 
release, we used VSV, a  nonneuraminidase  containing  virus, as a  control to ensure 
that our purification procedure removed the exogenous bacterial neuraminidase from 384  MATURATION OF  ENVELOPED  VIRUSES 
TABLE  II 
Effect of CB on Production of lnfluenza  Viral N'ase 
Virus  CB treatment  N'ase activity*  Percentage of 
control 
NA U/mg viral 
#g/ml  protein  % 
Influenza A/WSN  0  2.84  100 
Influenza A/WSN  50  0.29  10.0 
VSV  0  0.12  4.2 
* Specific N'ase activity of purified virus grown in MDBK cells. 1 neuramini- 
dase unit  (NAU) is defined as the amount of enzyme which releases neura- 
minic acid to produce an absorbance of 1.0 at a wave length of 549 nm, after 
a  1-h incubation. 
Fla.  3.  Autoradiograph of polypeptides of influenza A/WSN grown in MDBK cells which were 
treated with 50/~g/ml of CB (lane A) or grown in the absence of drug (lane B). Virus was grown in 
serum-free  medium containing 10 p.Ci/ml [3H]leucine, and purified and analyzed by SDS PAGE as 
described  in Materials and Methods.  Designations  of viral components are described in the text. 
the virus preparations.  The lack of detectable neuraminidase activity in VSV  indicates 
that  the  purification  procedure  effectively removed  the  exogenous  bacterial  neura- 
minidase. 
To rule out the possiblity that CB was capable of directly inhibiting neuraminidase 
activity, we determined  the neuraminidase  activity of purified  influenza virions with 
concentrations of 0-50 #g/ml  CB in the assay mixture (not shown).  CB did not inhibit 
the active neuraminidase of purified control virions. These results indicate that virions 
produced  in  drug-treated  cells  have  dramatically  impaired  neuraminidase  activity, 
and  that  CB  does  not  directly  inhibit  the  enzymatic  activity  of the  neuraminidase 
glycoprotein  (NA) of control  virions. 
Analysis  of Viral Polypeptides.  It  was possible  from  the results  described  above that JOHANNA A.  GRIFFIN AND  RICHARD W. COMPANS  385 
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FIG. 4.  SDS-PAGE of polypeptides of influenza A/WSN grown in untreated  (A) and CB-treated 
(50 #g/ml) MDBK cells (B) in serum-free medium. Infected cells were labeled with 1.5 p.Ci/m114C- 
amino acids and 10/tCi/ml  [3H]glucosamine, and virus was purified and analysed as described in 
Materials and Methods. 
virions  grown  in  CB-treated  cells  contained  an  inactive  form  of  the  viral  NA 
glycoprotein, or that  NA was absent  from these  virions,  possibly because  an  intact 
cytoskeletal network could be necessary for assembly of this glycoprotein with other 
viral components at the plasma membrane. To determine whether the NA glycopro- 
tein could be detected on CB-grown influenza virus, we analyzed the polypeptides of 
purified virions by SDS-polyacrylamide gel electrophoresis  (PAGE). Influenza virus- 
infected cells were grown in medium containing [aH]leucine with or without 50/~g/ 
ml CB. Cell monolayers were washed twice with serum-free medium before and after 
virus adsorption,  and serum  was excluded  from the  growth  medium  to prevent  the 
cleavage of HA into HA1 and HA2, which would interfere with resolution of the NA 
glycoprotein  (29).  5  U/ml  of  neuraminidase  were  included  in  the  maintenance 
medium  to enhance  the  release  of virus  from CB-treated  cells.  The purified  virions 
were then examined  by SDS-PAGE and  autoradiography  as shown in  Fig.  3.  Four 
major structural  proteins  could be resolved  in  control  as well  as CB-grown  virions. 
The membrane protein  (M)  and  the nucleoprotein  subunit  (NP)  were unaltered  by 
CB  treatment.  However,  the two glycoproteins,  HA and  NA, from CB-grown virus 386  MATURATION OF  ENVELOPED  VIRUSES 
Flo.  5.  SDS-PAGE of polypeptides of influenza A/WSN virions grown in untreated MDBK cells 
(right lane) or in MDBK cells treated with 50 p,g/ml of CB (left lane). Drug was added 6 h before 
infection and was also present post infection. The protein bands are stained with 0.2% Coomassie 
Brilliant Blue. The band designated  "A" corresponds to the component  identified  as actin.  The 
stained HA band  in  CB-grown virions is more  heterogeneous  and  has  a  faster electrophoretic 
mobility than the control band, as described for Fig. 3. 
(lane A) migrated more rapidly and were more heterogeneous than those of untreated 
control virus (lane B). These results suggested that glycosylation of viral glycoproteins 
might be impaired in the presence of CB. To further ex~tmine this possibility, we grew 
influenza virions in medium containing [3H]glucosamine and  14C-amino acids in the 
presence or absence of 50/~g/ml  CB. Again, serum-free conditions were maintained 
to  prevent  the cleavage of the  HA glycoprotein, and  exogenous  neuraminidase  was 
included to enhance virion release from CB-treated cells. The polypeptides of purified 
virions were analyzed on  7.5%  SDS polyacrylamide tube gels (Fig. 4). Again, M  and 
NP  proteins of CB-grown  and  control  virions were similar in  relative amounts  and 
electrophoretic mobilities, whereas the HA and NA glycoproteins in CB-grown virus 
(panel B)  migrated more rapidly and were more heterogeneous than those of control 
virus (panel A). [3H]glucosamine was specifically incorporated into both the HA and 
NA  glycoproteins of control  virions;  however  CB  treatment  nearly abolished incor- 
poration  of  glucosamine  label  into  the  viral  glycoproteins.  These  results  provide 
further  evidence  that  glycosylation of the  viral  glycoproteins  is  impaired  by  CB- 
treatment. 
Presence of Actin  in  CB-Grown  Virions.  It  seemed  possible  that  the  disruption  of JOHANNA  A.  GRIFFIN  AND  RICHARD  W.  COMPANS  387 
mirofilaments with CB may prevent the packaging of actin by influenza virus, which 
would  enable us  to examine a  possible role for actin  within  virions. We examined 
purified virions grown in the presence of CB for their ability to incorporate cellular 
actin.  Because  actin  was  not  labeled  under  conditions  used  to  examine  virion 
polypeptides in Figs. 3 and 4, influenza virus grown in the presence or absence of 50 
/~g/ml CB was purified and analyzed on polyacrylamide slab gels, which were stained 
with Coomassie Blue. In gels of both CB-treated and untreated virions (Fig. 5) there 
was a stained band at ~45,000 daltons, corresponding to the component identified as 
actin  (4).  In several experiments in  which  CB was added  to cells at  different  times 
before  or  after  influenza  virus  infection,  a  higher  level  of actin  was  reproducibly 
associated with virions from CB-treated cells than with virions from untreated control 
cells (data not shown). These results indicate that CB treatment did not inhibit  the 
association  of actin  with  enveloped  virions.  Therefore,  the  incorporation  of actin 
within enveloped virus particles, like the maturation of these particles, is independent 
of an intact cytoskeletal network. 
Discussion 
Several lines of evidence have suggested that the cytoskeletal network, and specifi- 
cally actin microfilaments, may be required  for some aspect of the assembly of viral 
components at the plasma membrane or for the budding of enveloped viruses. Wang 
and  coworkers  (4)  have  found  cellular  actin  in  purified  preparations  of influenza, 
Sendai,  Newcastle disease, and RNA tumor viruses, and Damsky and coworkers (5) 
observed microfilaments in close association with budding murine mammary tumor 
virus. Tyrrell and Ehrnst  (30)  found that CB in low concentrations (2/~g/ml) did not 
inhibit  the  cocapping of membrane-associated  matrix  protein  and  glycoprotein  of 
measles  virus  in  the  presence  of viral  glycoprotein-specific antibody,  but  that  the 
nucleocapsid  did  not  cap  under  these  conditions.  These  authors  suggested  that 
polymerized actin  may be required  for the association of nucleocapsid  with  matrix 
protein. The experiments outlined in this paper were undertaken to determine whether 
or not an intact cytoskeletal network is required for the functional association of viral 
components and for the budding of enveloped viruses. 
To  disrupt  actin  microfilaments we employed  the  drug CB,  which  inhibits  the 
polymerization  of contractile  elements  and  impairs  cellular  functions  which  are 
dependent upon that process (6-9). This drug is also known to inhibit hexose transport 
across  the  plasma  membrane  (9-13),  resulting  in  decreased  glycosylation  of both 
cellular and viral glycoproteins. The decrease in influenza virus yields which resulted 
from CB treatment in our studies was proportional to the concentration of the drug 
added;  50  /lg/ml  caused  a  100-fold  reduction  in  virus  titers.  We  found  that  this 
apparent reduction was not a  result of an inhibition of virus particle production but 
rather  a  result  of the  formation  of large  aggregates  of particles  adhering  to  cell 
surfaces, with  impaired release of particles  into  culture  medium.  The formation of 
aggregates and the failure of influenza virus to be released into culture medium under 
conditions  in  which  viral  neuraminidase  activity was  impaired  has been  described 
previously. Both influenza virus mutants with a  ts defect in NA (27)  and wild type 
influenza  virus  in  the  presence  of FANA,  a  neuraminidase  inhibitor  (28),  exhibit 
aggregation similar to that which we observed in CB-treated cultures. In both previous 
reports,  the  addition  of purified  bacterial  neuraminidase  resulted  in  disruption  of 388  MATURATION OF ENVELOPED VIRUSES 
virus aggregates and a concurrent elevation in virus titers. It was proposed from those 
results that the HA glycoprotein binds to neuraminic acid on viral and cell surfaces, 
and that virus release occurs only when the NA glycoprotein cleaves neuraminic acid, 
the  HA  receptor,  from  these  surfaces.  In  our  studies,  the  addition  of exogenous 
neuraminidase  to  CB-treated,  influenza  virus-infected  cultures  also  resulted  in  a 
greater than 30-fold increase in HA titers. Our results provide evidence that particle 
production in drug-treated cells was not significantly impaired, whereas neuramini- 
dase activity in virions from such cells was reduced by 90%. 
Because of the  report  (30)  that  nucleocapsids  may  not  become associated  with 
matrix protein of measles virus when microfilament function is inhibited, it was of 
utmost  importance  to  determine  if  virions  released  from  CB-treated  cells  were 
complete, i.e., were not lacking the viral genome. We found that upon neuraminidase 
treatment of CB-grown influenza virus, the increase in the infectivity titers roughly 
paralleled the increase in HA titers. This result indicates that the process of assembly 
of functional enveloped virions is not dependent on cytoskeletal elements. 
Examination of the structural polypeptides revealed that influenza virions produced 
in  CB-treated cells contained glycoproteins altered in electrophoretic mobility and 
unlabeled by [aH]glucosamine. This result was not surprising, because CB is known 
to inhibit the uptake of carbohydrate precursors. Dix and Courtney (31)  and Marci- 
ano-Cabral et al. (32) found that treatment of herpes simplex virus-infected cells with 
50 or 100 ~g/ml CB resulted in a 96% reduction in the yield of infectious virus and an 
accumulation of nucleocapsids in the nuclei of treated cells.  It was suggested that CB- 
induced  inhibition  of glycosylation  of ~'iral  membrane  components  may  inhibit 
recognition of the envelopment site by the herpes virus nucleocapsid. In our studies, 
it was of interest that such inhibition may inactivate the NA glycoprotein but did not 
noticeably impair  HA  activity or  the  envelopment of the  viral  genome.  Previous 
results  with  several  inhibitors  of  glycosylation  differ  from  our  results  with  CB. 
Hemagglutinin activity of influenza virus from cells treated with high concentrations 
of glucosamine or with the aberrant sugar 2-deoxy-D-glucose is markedly reduced, as 
is  the  infectivity of these  virions  (33-37).  Fluorosugars  also  inhibit  production  of 
active hemagglutinin  in Semliki forest virus and  in  fowl plague virus  (38).  Tunica- 
mycin,  an  antibiotic  which  completely  inhibits  glycosylation,  abolishes  the  HA 
activity of influenza virus, and noninfectious virions are produced (37, 39). In general, 
inhibition  of incorporation  of labeled  sugar  precursors  by  the  above  compounds 
appears to parallel the estimated degree of inhibition of glycosylation, as indicated by 
shift in electrophoretic mobility of the hemagglutinin glycoprotein. Complete inhibi- 
tion  of glycosylation  by  tunicamycin  results  in  production  of a  nonglycosylated 
hemagglutinin  polypeptide designated HA0 (tool wt  ~63,000), which migrates as a 
sharply  defined  band  in  SDS-polyacrylamide  gels  (37).  In  contrast,  CB  causes 
complete inhibition of the incorporation of labeled glucosamine into viral glycopro- 
teins, but probably only partially inhibits glycosylation, which results in the hetero- 
geneous population of HA molecules observed in electropherograms. Because of these 
contrasting results, it seems likely that the effect of CB on glycosylation is a secondary 
effect of its inhibition of sugar transport, resulting in a depletion of the intracellular 
pool of  carbohydrate precursors. The partial glycosylation of glycoproteins synthesized 
in  CB-treated  cells  is  suggested  by  the  electrophoretic  heterogeneity  of the  two 
influenza glycoproteins as well as the apparently unaltered HA activity; such partial JOHANNA A.  GRIFFIN AND  RICHARD W.  COMPANS  389 
glycosylation may enable incorporation  of neuraminic  acid  into CB-grown  virions. 
Our results also suggest that neuraminidase activity is more sensitive to this degree of 
glyeosylation  inhibition  than  is  hemagglutinin  activity;  however,  the  possibility 
cannot  be excluded that  formation of inactive neuraminidase  is a  result of another 
effect of CB. 
It is apparent  from our results  that  the maturation of enveloped viruses is not  a 
microfilament-dependent process. In fact, the disruption  of microfilaments does not 
appear to prevent the incorporation of actin into enveloped virions, indicating  that 
this process is also independent of a polymerized cytoskeleton. 
Summary 
The maturation of two enveloped viruses, influenza and vesicular stomatitis, occurs 
in  cells treated with cytochalasin  B.  Virions produced  in  the  presence of 50/~g/ml 
cytochalasin B  (CB) appear to be as infectious as those from control cells, indicating 
that polymerized actin is not required for the assembly of functional viral components. 
CB  inhibits  the  release of influenza  virus  from treated  cells,  a  phenomenon  which 
appears to be a result of the synthesis of an aberrant neuraminidase (NA) glycoprotein; 
virions grown in CB-treated cells had a  90% reduction in specific enzymatic activity. 
We found that both influenza viral glycoproteins (NA and Hemagglutinin glyco- 
protein)  had  faster electrophoretic  mobilities and were more heterogeneous  in  CB- 
treated  cells  as  compared with  controls.  We  also  observed  complete  inhibition  of 
incorporation of labeled glucosamine into viral glycoproteins in the presence of the 
drug. It was of interest that CB-induced inhibition of glycosylation appeared to cause 
loss of neuraminidase function, whereas hemagglutinating activity was not noticeably 
impaired.  The  presence of altered  glycoproteins did  not  significantly diminish  the 
infectivity of either influenza virus or vesicular stomatitis virus. 
Our results indicate that no step in the maturation of enveloped viruses is dependent 
upon an intact cytoskeletal network. 
We thank Mr. John Fitzpatrick for excellent  technical assistance. 
Received  for publication 23 April 1979. 
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